Spots Global Cancer Trial Database for stage i grade 1 follicular lymphoma

Every month we try and update this database with for stage i grade 1 follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Beta Alethine in Treating Patients With Low-Grade Lymphoma	NCT00007839	Lymphoma	beta alethine	18 Years -	National Cancer Institute (NCI)
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma	NCT00278161	Leukemia Lymphoma	Pegfilgrastim Rituximab Cyclophosphamid...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma	NCT00110149	Lymphoma	rituximab yttrium Y 90 ib...	18 Years - 120 Years	Beth Israel Deaconess Medical Center
Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma	NCT00310167	Lymphoma	radiation thera...	18 Years -	University College, London
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma	NCT00784927	Lymphoma	rituximab cyclophosphamid... dexamethasone lenalidomide	18 Years - 120 Years	Mayo Clinic
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma	NCT00003356	Lymphoma	aldesleukin rituximab	18 Years - 75 Years	University of Rochester
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)	NCT00005626	Leukemia Lymphoma	Irinotecan	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers	NCT00003572	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT01045928	Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac...	lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom...	18 Years -	Case Comprehensive Cancer Center
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma	NCT00006252	Leukemia Lymphoma	fludarabine pho... Cyclophosphamid... PBSC G-CSF Donor lymphocyt...	- 69 Years	Alliance for Clinical Trials in Oncology
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma	NCT00258336	Lymphoma	autologous immu... rituximab sargramostim	18 Years -	National Cancer Institute (NCI)
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma	NCT00551239	Leukemia Lymphoma	rituximab fludarabine pho... pixantrone dima...	18 Years - 120 Years	CTI BioPharma
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma	NCT00411086	Lymphoma	Rituximab Sargramostim (G...	18 Years -	M.D. Anderson Cancer Center
Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma	NCT00089115	Lymphoma	autologous immu... rituximab sargramostim	18 Years -	National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma	NCT00014326	Lymphoma	radiation thera...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia	NCT00004084	Leukemia Lymphoma	indium In 111 L... yttrium Y 90 ep...	18 Years -	Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer	NCT00004061	Leukemia Lymphoma Oral Complicati...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera...	18 Years - 65 Years	National Cancer Institute (NCI)
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer	NCT00004061	Leukemia Lymphoma Oral Complicati...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera...	18 Years - 65 Years	National Cancer Institute (NCI)
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00026351	Leukemia Lymphoma	rituximab pentostatin	18 Years -	National Cancer Institute (NCI)
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma	NCT00110149	Lymphoma	rituximab yttrium Y 90 ib...	18 Years - 120 Years	Beth Israel Deaconess Medical Center
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma	NCT00411086	Lymphoma	Rituximab Sargramostim (G...	18 Years -	M.D. Anderson Cancer Center
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma	NCT00551239	Leukemia Lymphoma	rituximab fludarabine pho... pixantrone dima...	18 Years - 120 Years	CTI BioPharma
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan	NCT00577278	Graft Versus Ho... Leukemia Lymphoma	rituximab fludarabine pho... melphalan sirolimus tacrolimus allogeneic hema... indium In 111 i... yttrium Y 90 ib... laboratory biom...	18 Years - 69 Years	City of Hope Medical Center
Beta Alethine in Treating Patients With Low-Grade Lymphoma	NCT00007839	Lymphoma	beta alethine	18 Years -	National Cancer Institute (NCI)
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma	NCT01682044	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Margina... Stage I Small L... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Margi... Stage III Small... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Margin... Stage IV Small ...	pegfilgrastim rituximab flow cytometry biopsy immunohistochem... western blottin...	19 Years -	Roswell Park Cancer Institute
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas	NCT02213913	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Small Intestine... Splenic Margina... Stage 0 Chronic... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult H... Stage I Adult I... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Adult ... Stage II Chroni... Stage II Small ... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Testicular Lymp... Untreated Hairy... Waldenström Mac...	lenalidomide etoposide prednisone vincristine sul... doxorubicin hyd... cyclophosphamid... rituximab quality-of-life... laboratory biom...	18 Years -	University of Chicago
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma	NCT00258336	Lymphoma	autologous immu... rituximab sargramostim	18 Years -	National Cancer Institute (NCI)
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	NCT02037256	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Refractory Mult... Small Intestine... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Multipl... Stage I Small L... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Untreated Hairy... Waldenström Mac...	bortezomib filgrastim autologous hema...	18 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer	NCT00004132	Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera...	12 Years - 65 Years	National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma	NCT00551239	Leukemia Lymphoma	rituximab fludarabine pho... pixantrone dima...	18 Years - 120 Years	CTI BioPharma
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma	NCT00003337	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma	NCT00004260	Lymphoma	recombinant int... rituximab	18 Years -	Mayo Clinic
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers	NCT00003658	Leukemia Lymphoma	filgrastim rituximab cyclophosphamid... pentostatin	18 Years -	Memorial Sloan Kettering Cancer Center
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant	NCT00002657	Lymphoma Multiple Myelom...	bleomycin sulfa... recombinant int... cyclophosphamid... cytarabine doxorubicin hyd... etoposide methotrexate prednisone vincristine sul... conventional su... radiation thera...	15 Years -	SWOG Cancer Research Network
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma	NCT00720876	Lymphoma	rituximab vorinostat	18 Years -	City of Hope Medical Center
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Beta Alethine in Treating Patients With Low-Grade Lymphoma	NCT00007839	Lymphoma	beta alethine	18 Years -	National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00003615	Lymphoma	denileukin dift...	18 Years - 120 Years	Eastern Cooperative Oncology Group
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma	NCT01682044	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Margina... Stage I Small L... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Margi... Stage III Small... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Margin... Stage IV Small ...	pegfilgrastim rituximab flow cytometry biopsy immunohistochem... western blottin...	19 Years -	Roswell Park Cancer Institute
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers	NCT00003658	Leukemia Lymphoma	filgrastim rituximab cyclophosphamid... pentostatin	18 Years -	Memorial Sloan Kettering Cancer Center
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma	NCT00290667	Lymphoma	pegfilgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... pharmacological... radiation thera...	61 Years - 80 Years	Universität des Saarlandes
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer	NCT00816413	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... Nonmalignant Ne...	cyclosporine mycophenolate m... pentostatin cytogenetic ana... fluorescence in... protein analysi... flow cytometry immunoenzyme te... laboratory biom... reduced-intensi... nonmyeloablativ... peripheral bloo... total-body irra...	19 Years - 75 Years	University of Nebraska
Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma	NCT00310167	Lymphoma	radiation thera...	18 Years -	University College, London
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers	NCT00003572	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma	NCT00058227	B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Chro... Refractory Hair... Splenic Margina... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Chroni... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Untreated Hairy... Waldenström Mac...	alvocidib fludarabine pho... rituximab pharmacological...	18 Years -	National Cancer Institute (NCI)
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT00288067	Adult Nodular L... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Stage II Margin... Stage II Small ... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult H... Stage I Adult L... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Small L... Stage II Adult ... Stage II Chroni... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	fenretinide rituximab	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: